A Study to Evaluate Safety of ASC40 Tablets in Patients with Moderate to Severe Acne Vulgaris

Inclusion Criteria:

• Participants who have successfully completed a 12-week Phase III study of ASC40-303;

• Have fully understood this research and voluntarily signed the informed consent;

• The fertile male and female subjects of reproductive age agreed to use effectivecontraception from the time they signed the informed consent until 3 months afterthe final administration of the investigationa drug;

• Subjects are willing and able to complete the study, understand and comply with thestudy requirements, comply with the study requirements restrictions and relatededucation, use the investigational drug as prescribed by the physician, and followup according to the study schedule.

Exclusion Criteria:

• Discontinue participation in the ASC40-303 Phase III study for any reason;

• Are receiving/planning to receive any systemic acne medications, systemic retinoids,systemic corticosteroids, or any androgen/antiandrogen therapy (e.g., testosterone,spironolactone);

• Pregnant, nursing, or planning a pregnancy during the study period;

• Have major complications (including clinically significant abnormalities in clinicallaboratory tests), mental disorders, or other factors deemed unsuitable for studyparticipation by the investigator.